Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

GPs told to give accelerated MMR boosters to 90,000

Potential cost savings from the Government's £1.8 billion price-cutting deal with the drug industry could have little impact, GP experts have warned.

The voluntary pharmaceutical price regulation scheme deal, agreed last week, will shave 7 per cent off the cost of branded drugs for the NHS, and the Department of Health said money saved would be ploughed back into PCTs.

Health Secretary John Reid said the deal was a 'win-win' for the NHS, the taxpayer, and the drug industry with industry tax breaks on research rising by 5 per cent.

But Dr Mike Dixon, chair of the NHS Alliance, said PCTs were unlikely to have more money for services because many trusts were still wrestling with overspends.

RCGP prescribing spokesman Dr Jim Kennedy, a GP in Hayes, Middlesex, said the deal would have little overall impact because of consistent increases in the number of prescriptions.

In 1999 the NHS and the drug industry made a deal which saved the NHS 4.5 per cent of its drugs bill, but critics said NHS prescribing costs had doubled since then.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say